OXGENE TESSA Technology Overview
TESSA™ technology addresses the industry-wide challenge of robust, reproducible, and scalable AAV manufacture, while avoiding the costs and bottlenecks of GMP plasmid-based production.
TESSA™ vectors can provide high quality help for AAV manufacture, but unlike the wildtype virus, they cannot produce adenoviral structural proteins. This reduces adenoviral contamination by 99.9999 - 100% in a manufacturing run, while also delivering high viral yields at a considerably lower cost than three-plasmid-transfection. Increased vector quality and infectivity also raises the potential of delivering safer gene therapies at a lower effective dose...
Download our free resource now.